Lilly's Zyprexa: A Victim of Its Past Success
This article was originally published in RPM Report
Executive Summary
Antipsychotics in general-and Lilly's Zyprexa in particular-may be the products taking the biggest hit from health care reform. The only thing worse was the alternative.
You may also be interested in...
Taking Lumps From Health Care Reform
Big Pharma's first quarter earnings reports offered the first estimates of the impact from health care reform on the industry. Wall Street was taken aback at the size of some of the hits. But not everyone is equally affected-nor will everyone be feeling the same burden when new impacts begin in 2011.
Taking Lumps From Health Care Reform
Big Pharma's first quarter earnings reports offered the first estimates of the impact from health care reform on the industry. Wall Street was taken aback at the size of some of the hits. But not everyone is equally affected-nor will everyone be feeling the same burden when new impacts begin in 2011.
Health Care Reform and the Biopharma Sector: A Complete Tactical Victory
The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: